Study guide
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs
Key Takeaways Explain This Topic AI
A collaborative pharmacy practice agreement in Utah is a written and signed agreement between one or more pharmacists and one or more practitioners for drug therapy management, initiating therapy, and disease prevention (Utah Code § 58-17b-102(17)).
Under a collaborative agreement, Utah drug therapy management may include modifying therapy, reviewing histories, checking vital signs, and ordering and evaluating lab tests under approved protocols (R156-17b-611(1)).
Before administering a prescription drug, a Utah pharmacist or intern must have current BLS certification, injection training for injectables, drug-specific training, and anaphylaxis-management training (R156-17b-621).
A Utah pharmacist may give a long-acting injectable or naloxone intramuscularly only after ACPE-accredited training, at a clinic or community pharmacy, and as directed by the prescribing physician (Utah Code § 58-17b-625).
A Utah pharmacist may prescribe a nebulizer, spacer, or diabetic supplies needed to deliver a prescribed drug, and must notify the prescriber within five business days (Utah Code § 58-17b-610.8; R156-17b-612a).
Last updated: September 2026
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs
Blueprint item 2.2 covers the conditions under which pharmacists and other staff take part in "the administration of drugs in the management of patients' therapy." In Utah this covers four tools: collaborative practice agreements , drug therapy management (DTM) , drug administration , and device prescribing . Pharmacist prescribing under public-health guidance is covered in Sections 6.2 and 6.3.
Collaborative pharmacy practice
The Pharmacy Practice Act defines the key terms:
Collaborative pharmacy practice : a practice in which one or more pharmacists have agreed, on a voluntary basis , to work with one or more practitioners under protocol , so the pharmacist may perform certain pharmaceutical care functions the practitioners authorize, under specified conditions or limits (§ 58-17b-102(16)).
Collaborative pharmacy practice agreement : a written and signed agreement between one or more pharmacists and one or more practitioners that provides for collaborative practice "for the purpose of drug therapy management of patients, initiating therapy , and prevention of disease " (§ 58-17b-102(17)).
The practice of pharmacy includes collaborative practice under an agreement (§ 58-17b-102(58)(b)). A prescription includes an order issued "by collaborative pharmacy practice agreement" (§ 58-17b-102(63)).
Utah's statute and rule do not prescribe a detailed form for the agreement, a fixed review interval, or an insurance requirement. What they require is that the agreement be written and signed , be voluntary , and operate under protocol within limits the practitioner may lawfully delegate. The agreement cannot give the pharmacist more authority than the collaborating practitioner has. A pharmacy applying for a Class D license must describe any collaborative practice arrangements in its protocol (§ 58-17b-306(2)(f)).
Drug therapy management (R156-17b-611(1))
Decisions involving DTM "shall be made in the best interest of the patient." DTM may include:
- implementing, modifying, and managing drug therapy according to the collaborative agreement;
- collecting and reviewing patient histories ;
- obtaining and checking vital signs (pulse, temperature, blood pressure, respiration);
ordering and evaluating laboratory tests directly related to drug therapy, when done under approved protocols for the practice setting; and
other patient-care services allowed by rule.
Note
DTM under a collaborative agreement is separate from the DUR every pharmacist performs at dispensing (R156-17b-611(2)–(3); Section 5.2). A collaborative agreement adds authority; it does not replace DUR.
Administration of drugs
Administration is part of the practice of pharmacy when it is done under a lawful order of a practitioner (when one is required) and under written guidelines or protocols . For inpatients, those protocols are set by the facility. For outpatients, when the pharmacist alone administers, they must be approved by DOPL with the board and, when appropriate, the Medical Licensing Board (§ 58-17b-102(58)(c)).
Training (R156-17b-621)
Before administering a prescription drug or device, a pharmacist or intern must complete:
- current Basic Life Support (BLS) certification;
- for injectables, didactic and practical training in administering injectable drugs;
- training on the specific drug or device being administered;
- for vaccines, current ACIP guidelines; and
training in management of an anaphylactic reaction .
A technician who administers needs the BLS, injection, and anaphylaxis training. Acceptable training sources include ACPE-approved programs, college of pharmacy or ASHP-accredited technician curricula, health department programs, and other board-recognized providers. Each person who administers must keep documentation of the training and complete two hours of related CE each renewal cycle (R156-17b-621(4); R156-17b-309).
Administering without appropriate training , without a physician's order when the law requires one , or contrary to a practitioner's written guidelines or protocol is unprofessional conduct (§ 58-17b-502(1)(i)).
Long-acting injectables and naloxone (§ 58-17b-625; R156-17b-621a)
A pharmacist may administer naloxone or a long-acting injectable (for example, a long-acting antipsychotic or buprenorphine formulation) intramuscularly only if the pharmacist:
has completed current BLS and an ACPE-accredited training program for intramuscular long-acting injectables, and keeps documentation;
administers the drug at a clinic or community pharmacy as DOPL defines those terms (a Class B pharmacy or qualifying outpatient facility, or a Class A pharmacy); and
is directed by the physician who issues the prescription to administer it.
Pharmacist prescribing of devices (§ 58-17b-610.8; R156-17b-612a)
For nebulizers , spacers for nebulizers or inhalers, and diabetic supplies :
A written prescription, or a written record of the patient's current diagnosis or treatment protocol on file at the pharmacy, counts as a prescription for the device.
A pharmacist may prescribe one of these devices when it is not covered by the document on file and the pharmacist decides it is necessary for appropriate delivery of the prescribed drug . The prescribing practitioner on the underlying document is treated as the device's prescriber.
The pharmacist determines the dispense quantity, directions, and refills, and dispenses from a Class A or B pharmacy.
The pharmacist must notify the prescribing practitioner within five business days , in writing, electronically, or by phone, giving the pharmacy name and phone number, patient, quantity, directions, and refills.
A pharmacist may also dispense a therapeutic equivalent when filling a prescription for a glucometer, test strips, lancets, syringes, needles, or other designated diabetes supplies (§ 58-17b-608.2(7); R156-17b-612b(2)).
Public health prescriptions (§ 58-17b-620)
To treat a reportable disease or a non-emergency condition that directly affects public health, a health department may use special procedures for non-controlled drugs. These cover STI treatment, fluoride, travel immunizations, latent TB treatment, and other preventive treatment at clinics or temporary sites. A physician may sign serially numbered prescriptions without the patient's name, address, and date , and a health department registered nurse completes them under standing written orders and an approved protocol. A prescriber may also write prescriptions for a patient's contacts without a face-to-face exam. A health department nurse may dispense prepackaged STI drugs under R156-17b-628.
Exam traps
A verbal "manage her warfarin" instruction is not a collaborative practice agreement. The agreement must be written and signed .
Collaborative practice does not let a pharmacist make independent diagnoses outside the protocol.
Vaccines follow a separate protocol (Section 6.4). Long-acting injectables and naloxone IM require the training, setting, and physician-direction conditions of § 58-17b-625.